cancer Cancer Discovery Cancer screening Clinical Trials

Early Clinical Trial Data Show Gene Therapy Reversing Sickle Cell Anemia

After over a decade of preclinical research and development, a new gene therapy treatment for Sickle Cell Anemia (SCA) is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.  Preliminary data from a pilot Phase 1-2 clinical trial testing the gene-addition therapy were presented Dec. 3 at the American Society of Hematology’s (ASH) annual meeting in San
Biotechnology Cell Therapy Clinical Trials Immunotherapies stem cells

Dana-Farber researchers report clinical trial results in treatment of leukemia and lymphoma

New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4.  Here are summaries of three presentations, including one that compared outcomes of CAR T-cell therapy in patients in clinical trials with outcomes in the “real world” of clinical practice: CAR T-cell treatment provides durable
Biotechnology Clinical Trials Research & Discovery

WVU first site to launch clinical trial utilizing non-opioid micropellet implant for chronic pain

As part of an ongoing commitment to battle opioid addiction, the Rockefeller Neuroscience Institute at West Virginia University today marked a major milestone, enrolling the first patient in a randomized clinical trial that will test the effectiveness of an injectable non-opioid, non-steroid micropellet to treat sciatica. The phase III clinical trial utilizes a clonidine micropellet, which is half the size of a grain of rice and is placed in a
Biotechnology cancer Clinical Trials

Researchers Use New AI Techniques in Clinical Trials for Personalized Cancer Treatment

Researchers are finding new ways to use artificial intelligence and nanotechnology to enhance treatments, from routine dental techniques to attacking cancerous tissue. At the AVS 65th International Symposium and Exhibition, being held Oct. 21-26, 2018, in Long Beach, California, Dean Ho will present the results of two clinical trials that show how AI-enabled personalized medical treatment for a prostate cancer patient and nanotechnology improved recovery for patients after a root
cancer Clinical Trials drug development Surgery

Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage 3 Melanoma

Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early. The phase II study was led by researchers at The University of Texas MD Anderson Cancer Center. Results of the study, the first randomized neoadjuvant clinical trial
Biotechnology Breast Cancer cancer Cancer Discovery Cancer screening Clinical Trials genes

New Study Finds Nanoparticles Show Promise in Therapy for Triple-Negative Breast Cancer

Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer. Triple-negative breast cancer can be more aggressive and difficult to treat as the cancer cells do not respond to hormonal therapies or therapies that target HER2 receptors. A new
Clinical Trials

Enhanced Rehab for Stroke Doubles Movement Recovery

 A novel therapy technique invented by researchers at The University of Texas at Dallas has been shown in a pilot study to double the rate of upper limb recovery in stroke patients, a leap forward in treating the nearly 800,000 Americans who suffer strokes each year. The results of the study, funded by UT Dallas spinoff company MicroTransponder of Austin, Texas, were published Sept. 27 in the journal Stroke. The findings
Biotechnology Clinical Trials stem cells

Human Neural Stem Cells Drive Spine Regeneration in Rats

Stem cells maintained in culture renewed long regions of spinal cord in rat transplant model NIBIB-funded researchers generated stable lines of spinal cord neural stem cells in a laboratory dish. Once transplanted into a rat model of spinal cord injury, the cells enabled robust regeneration of functional neurons along the length of the spine. The research team  from the University of California, San Diego, used human pluripotent stem cells (hPSCs)
Biotechnology Clinical Trials Gene Therapy genes

Proof of Concept Study Aims for Rapid Genotyping to Guide Epilepsy Treatment

An easy and inexpensive test for the HLA-B*15:02 allele could one day allow clinicians to quickly identify which epilepsy patients are at risk of carbamazepine hypersensitivity, according to study results presented by Gita V. Soraya at ILAE's 2018 Asian & Oceanian Epilepsy Congress in Bali. “This study has provided the proof of principle evidence for the development of a handheld device that can be used at the clinic or bedside
Breast Cancer cancer Cancer Discovery Clinical Trials

Researchers to Test Novel Drug Combination Against Toughest Breast Cancers

Phase I clinical trial will combine standard chemotherapy with cirmtuzumab, a drug that has shown promise against a variety of cancer types Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed. Cirmtuzumab is a novel monoclonal antibody
Antibiotics Clinical Trials drug development rare diseases

Taking a Pill Can Effectively Treat Brutal Lung Disease

Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis (PAP), and they show taking cholesterol-busting pills called statins can effectively treat the disease. That’s good news for people with PAP because at present the current standard treatment is something called a whole lung lavage. Essentially, it involves flushing patient
Clinical Trials

Eating Crickets Can Be Good for Your Gut, According to New Clinical Trial

Valerie Stull was 12 when she ate her first insect. “I was on a trip with my parents in Central America and we were served fried ants,” she says. “I remember being so grossed out initially, but when I put the ant in my mouth, I was really surprised because it tasted like food — and it was good!” Today, Stull, a recent doctoral graduate of the University of Wisconsin–Madison Nelson
Clinical Trials

A hangover pill? Tests on drunk mice show promise

By bogdanhoda/Shutterstock.com Yunfeng Lu, University of California, Los Angeles “Civilization begins with distillation,” said William Faulkner, a writer and drinker. Although our thirst for alcohol dates back to the Stone Age, nobody has figured out a good way to deal with the ensuing hangover after getting drunk. As a chemical engineering professor and wine enthusiast, I felt I needed to find a solution. As frivolous as this project may sound,
Biotechnology Clinical Trials Pharmaceuticals rare diseases

New Insight Into Huntington’s Disease May Open Door to Drug Development

McMaster University researchers have developed a new theory on Huntington’s disease which is being welcomed for showing promise to open new avenues of drug development for the condition. Huntington’s disease is caused by a mutation in the gene that makes the protein called huntingtin. A team of researchers led by McMaster has found there is a unique type of signalling coming from damaged DNA, that signals huntingtin activity in DNA
Biotechnology cancer Clinical Trials Uncategorized

Brain metastases common and difficult to treat in ROS1 lung cancer

Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes. However, these cancers are not only dangerous in the lung where they appear, but can become especially dangerous if they are able to metastasize to the brain – a
Biotechnology Clinical Trials Diabetes

Experimental Drug Stops Parkinson’s Disease Progression in Mice

Johns Hopkins researchers say they have developed an experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson’s disease itself — as well as its symptoms — in mice. In experiments performed with cultures of human brain cells and live mouse models, they report the drug blocked the degradation of brain cells that is the hallmark of Parkinson’s disease. The drug is expected to move
cancer Cancer Discovery Clinical Trials

Seattle Children’s Opens Immunotherapy Trial For Children With Relapsed Central Nervous System Tumors That Delivers CAR T Cells Directly Into the Brain

CAR T-cell immunotherapy targeting HER2 protein on cancer cells aims to provide children and young adults who have limited treatment options with a second line of defense Seattle Children’s has opened a pioneering chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory HER2-positive central nervous system (CNS) tumors where CAR T cells will be delivered directly into the brain. In the phase I
Biotechnology cancer Clinical Trials Prodrug

New Drug Combination Shows Promise in Treating Ovarian Cancer

Researchers at The University of Kansas Cancer Center have discovered a therapy combination that may be helpful in the treatment of certain types of ovarian cancer. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. According to the American Cancer Society, about 22,240 women are diagnosed with ovarian cancer each year. In a preclinical study led by Dineo
Biotechnology Clinical Trials Pharmaceuticals

A Change in Bacteria’s Genetic Code Holds Promise of Longer-Lasting Drugs

By altering the genetic code in bacteria, researchers at The University of Texas at Austin have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs' effectiveness and convenience, leading to smaller and less frequent doses of medicine, lower health care costs and fewer side effects for patients with cancer and other diseases. The results were published today in the journal Nature Biotechnology. [June 4, 2018]
cancer Cancer Discovery Clinical Trials

Magnetic Nanoparticles Leap From Lab Bench to Breast Cancer Clinical Trials

 Sandia National Laboratories materials chemist Dale Huber has been working on the challenge of making iron-based nanoparticles the exact same size for 15 years. Now, he and his long-term collaborators at Imagion Biosystems will use these magnetic nanoparticles for their first breast cancer clinical trial later this year. The nanoparticles stick to breast cancer cells, allowing the detection and removal of even small metastases. Imagion Biosystems and Huber have been working together